DOA
BCLI

D'Orazio & Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

D'Orazio & Associates’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-67
Closed -$4K – 333
2017
Q1 		$4K Hold
67
– – ﹤0.01% 254
2016
Q4 		$3K Hold
67
– – ﹤0.01% 247
2016
Q3 		$2K Buy
+67
New +$2.51K ﹤0.01% 257
2016
Q2 		– Sell
-33
Closed -$1K – 295
2016
Q1 		$1K Buy
+33
New +$1.21K ﹤0.01% 278

Other funds holding BCLI

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

D'Orazio & Associates's BCLI Position: Q2 2017 in Review

D'Orazio & Associates sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2017, closing a stake of 67 shares — an estimated $4K sold.

D'Orazio & Associates first reported a position in BCLI in Q1 2016 and held it in 4 quarters. The position peaked at $4K in Q1 2017. 26 funds tracked by Wall St. Rank hold BCLI as of Q2 2017.

  • D'Orazio & Associates reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2017 after selling out during the quarter.
  • D'Orazio & Associates sold 67 BRAINSTORM CELL THERAPUTC shares in Q2 2017, an estimated $4K.
  • D'Orazio & Associates first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 4 quarters.
  • D'Orazio & Associates's BRAINSTORM CELL THERAPUTC position peaked at $4K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2017.

Based on D'Orazio & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.